• Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Vatseba M.O.


    About the author: Vatseba M.O.
    Type of article Scentific article
    Annotation Arterial hypertension (AH) is a topical issue of modern health care in Ukraine, which has a significant impact on cardiovascular morbidity and mortality. Comorbidity of AH remains an insufficiently studied problem. On the background of its widespread prevalence, there is an increase in the number of people with hypertension with obesity and gout. It is important to find common pathogenetic mechanisms that would determine the development and progression of hypertension, obesity and gout. One of these is the change in the parameters of systemic immune activation (CIA). It is believed that chronic systemic inflammation causes damage to the blood vessels endothelium. As a result, the synthesis of nitric oxide stops at the vessel wall and activates the renin-angiotensin-aldosterone system (RAAS). Treatment of patients against the background of metabolic risk factors needs an aggressive therapy. Special attention is paid to antihypertensive drugs, which have a positive metabolic effect. In view of the of pathogenetic mechanisms multiplicity in combination of hypertension, obesity and gout, the therapy should also be multipurpose. Therefore, a logical and promising field is the active search for drugs, and their combinations, which can effectively influence the various stages of AH formation, in particular the indicators of Systemic immuno inflammatory activation (SIIA). The purpose of the study was to eatimate the effect of losartan and meltedonium dihydrate on the parameters of systemic immune activation in patients having essential hypertension with obesity and gout. The study involved 80 patients with essential hypertension stage II, degree 2, combined with obesity and gout. Indicators of systemic immune activation under the influence of standard therapy in the dynamics did not significantly change. Losartan on the background of standard therapy significantly lowered the level of IL-6. After 6 months of treatment, its concentration in the blood decreased by 10.81% (p<0.05), and the level of CRP - by 17.31% (p<0.05). Meldonium dihydrate significantly reduced the CRP level after 1 month of treatment by 9.22% (p <0.01), and after 6 months - by 11.48% (p<0.001). It should be noted that the dynamics of systemic immun activation rates was most pronounced while combination losartan and meltedium dihydrate. This is evidenced by a decrease level of the CRP in the blood in 23.39% (p<0.001) after 1 month of treatment, and after 6 months - by 35.01% (p<0.001) and IL-6 content, respectively, by 40,15% (p<0.001) and 62.10% (p<0.001). Thus, it has been found that the combined use of losartan and meltedonium dihydrate against the background of standard therapy was much more effective in reducing the systemic immune activation compared with the separate administration of these drugs.
    Tags arterial hypertension; obesity; gout; systemic immunoactive activation
    • Klasyfikatsiia ta standarty nadannia medychnoi dopomohy khvorym na arterialnu hipertenziiu Asotsiatsii kardiolohiv Ukrainy. Robocha hrupa z arterialnoi hipertenzii ukrainskoi asotsiatsii kardiolohiv. Arterіa'na hіpertenzіia. 2018; 4(60): 28–32. [in Ukrainian].
    • Mishchenko LA, Svishchenko YeP, Bezrodnyi VP. Vplyv antyhipertertenzyvnykh preparativ na prozapalni ta metabolichni faktory sertsevo-sudynnoho ryzyku u khvorykh na hipertonichnu khvorobu. Halytskyi likarskyi visnyk. 2012;19(4): 55-58. [in Ukrainian].
    • Radchenko HD, Mushtenko LO, Sirenko YuM. Rehres urazhennia orhaniv-misheney na tli terapii fiksovanoyu kombinatsiyeyu peryndoprylu ta amlodypinu v patsiientiv z arterialnoyu hipertenziyeyu zalezhno vid naiavnosti ishemichnoyi khvoroby sertsia. Ukrainskyi kardiolohichnyi zhurnal. 2017; 4: 32-46. [in Ukrainian].
    • Sirenko YuM. Pro novi yevropeiski rekomendatsii z arterialnoyi hipertenziyi pislia yikh pershoyi prezentatsiyi (komentar). Arteryalna hypertenziya. 2018; 3 (59): 19-22. [in Ukrainian].
    • Strilchuk LM. Osoblyvosti adypotsytokinovoyi rehuliatsiyi v osib iz hipertonichnoyu khvoroboyu ta pidvyshchenoyu masoyu tila. Arterialna  hipertenziia. 2017; 3 (53) 71-72. [in Ukrainian].
    • Tashchuk VK, Vasek Obeid Al Salama Mukhamed. Komorbidnist, sertsevo-sudynna patolohiya i likuvannia hiperurykemiyi — chy zapobihaye zakhvoriuvanniu alopurynol? Bukov. med. visn. 2016; 20(2): 209–212. [in Ukrainian].
    • Cibičková Ľ, Langová K, Vaverková H et al. Correlation of uric acid levels and parameters of metabolic syndrome. Physiol. Res. 2017; 66(3): 481–487.
    • Kuwabara M. Hyperuricemia, Cardiovascular Disease, and Hypertension. Pulse (Basel). 2016; 3 (3–4): 242-252.
    • Martínez-Quintana E, Tugores A, Rodríguez-González F. Serum uric acid levels and cardiovascular disease: the Gordian knot. J. Thorac. Dis. 2016; 8(11): 1462–1466.
    • Reviño-Becerra A. Uric Acid: The unknown uremic toxin. Contrib. Nephrol. 2018; 192(1): 25–33.
    Publication of the article «World of Medicine and Biology» №2(68), 2019 year, 159-162 pages, index UDK 615.272+616.12-008.331.1++616-056.52++616.72-002.78
    DOI 10.26724/2079-8334-2019-2-68-159-162